About Anika Therapeutics, Inc.
https://www.anikatherapeutics.comAnika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally.
CEO
Cheryl Renee Blanchard
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 80
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:1.74M
Value:$16.62M
TRIGRAN INVESTMENTS, INC.
Shares:1.62M
Value:$15.47M
BLACKROCK INC.
Shares:1.61M
Value:$15.33M
Summary
Showing Top 3 of 169
About Anika Therapeutics, Inc.
https://www.anikatherapeutics.comAnika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $27.82M ▼ | $18.82M ▲ | $-2.33M ▲ | -8.37% ▲ | $-0.16 ▲ | $-833K ▲ |
| Q2-2025 | $28.22M ▲ | $18.54M ▼ | $-3.97M ▲ | -14.07% ▲ | $-0.28 ▲ | $-2.76M ▼ |
| Q1-2025 | $26.17M ▲ | $18.96M ▲ | $-4.87M ▲ | -18.62% ▼ | $-0.34 ▲ | $-2.69M ▼ |
| Q4-2024 | $-1.29M ▼ | $-5.25M ▼ | $-21.86M ▲ | 1.69K% ▲ | $-1.5 ▲ | $26.53M ▲ |
| Q3-2024 | $38.75M | $29.46M | $-29.92M | -77.2% | $-2.03 | $-25.42M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $57.99M ▲ | $189.44M ▲ | $42.63M ▲ | $146.81M ▼ |
| Q2-2025 | $53.17M ▼ | $187.68M ▼ | $40.01M ▼ | $147.67M ▼ |
| Q1-2025 | $53.37M ▼ | $190.6M ▼ | $42.21M ▼ | $148.4M ▼ |
| Q4-2024 | $55.63M ▼ | $202.74M ▼ | $48.75M ▼ | $153.99M ▼ |
| Q3-2024 | $62.37M | $231.41M | $51.54M | $179.86M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.33M ▲ | $6.87M ▲ | $-1.73M ▼ | $-13K ▼ | $4.82M ▲ | $4.98M ▲ |
| Q2-2025 | $-3.97M ▲ | $-189K ▼ | $-539K ▼ | $179K ▲ | $-204K ▲ | $-1.66M ▲ |
| Q1-2025 | $-4.87M ▲ | $-130K ▼ | $1.67M ▲ | $-5.44M ▼ | $-3.79M ▲ | $-2.95M ▼ |
| Q4-2024 | $-21.86M ▲ | $1.58M ▼ | $-1.31M ▲ | $-5.35M ▼ | $-5.21M ▼ | $275K ▼ |
| Q3-2024 | $-29.92M | $5.02M | $-1.82M | $-3.99M | $-454K | $3.2M |
Revenue by Products
| Product | Q4-2023 | Q1-2024 | Q2-2024 | Q3-2024 |
|---|---|---|---|---|
 Joint Preservation and Restoration | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 NonOrthopedic | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Europe | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
 UNITED STATES | $30.00M ▲ | $20.00M ▼ | $20.00M ▲ | $20.00M ▲ |
CEO
Cheryl Renee Blanchard
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 80
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:1.74M
Value:$16.62M
TRIGRAN INVESTMENTS, INC.
Shares:1.62M
Value:$15.47M
BLACKROCK INC.
Shares:1.61M
Value:$15.33M
Summary
Showing Top 3 of 169